Loading…
Biotech developing muscle-targeted drugs, including aficamten for hypertrophic cardiomyopathy, awaiting its first approval.
Biotech developing muscle-targeted drugs, including aficamten for hypertrophic cardiomyopathy, awaiting its first approval.
Has lived on partner payments, royalty-financing deals and share sales rather than product sales, with trial and launch costs funded from outside. The business is built around one drug class, cardiac myosin inhibitors, which act directly on how heart muscle contracts.
Moat: narrow (IP / patents, process know-how). Deep expertise in cardiac muscle mechanics from a long-running R&D heritage tied to Amgen.
Headquarters: South San Francisco, California, United States · Founded: 1997 · Employees: 673
Size Cytokinetics (CYTK) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.46B, the 931st largest of 3,117 United States companies the cockpit tracks. Shares closed at $53.69 on 6 Nov 2026.
Performance Over six months the shares fell 30.2%, against +6.7% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 21.1% over the last twelve months (peer median +10.4%); the operating margin is -1,046.1% (peer median 16.9%).
Valuation It trades at 111.8× enterprise value to sales against a peer median of 4.5× (most expensive of 19).
Credit Cytokinetics has 2 bonds outstanding ($891M).
Short interest Short interest is 13.4% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $67.7M | $88.0M | $18.5M | $7.53M | $94.6M |
| Revenue growth | — | +377% | +145% | -92% | — |
| Gross profit | $47.0M | $77.9M | $8.94M | -$4.36M | $86.2M |
| EBITDA | -$695M | -$602M | -$527M | -$484M | -$316M |
| Net income | -$894M | -$785M | -$590M | -$526M | -$389M |
| Free cash flow | -$581M | -$535M | -$400M | -$416M | -$311M |
| Capital expenditure | $25.3M | $24.8M | $3.91M | $1.42M | $11.3M |
| Total debt | $1.27B | $1.28B | $789M | $756M | $749M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Cytokinetics CYTK | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Edgewise Therapeutics EWTX | $4.89B | +28% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CYTK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.4% | +4.4% | 3rd lowest of 21 |
| 6-month return | -30.2% | +6.7% | 3rd lowest of 21 |
| Distance from 52-week high | -39.2% | -10.8% | 4th lowest of 21 |
| Revenue growth (TTM) | -21.1% | +10.4% | 2nd lowest of 20 |
| Operating margin | -1,046.1% | 16.9% | lowest of 19 |
| EV / Sales | 111.8× | 4.5× | most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 7.2× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 8.7× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 1.1× | -2.7% | +5.3% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% | +7.3% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 4.1× | 20.0% | +9.4% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | 27.4× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 7.9× | 24.9% | +16.6% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | 2.4× | -9.1% | +6.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 2.0× | -6.1% | +9.3% |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 5.1× | -4.8% | +57.9% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 6.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 7.8× | 7.6% | +12.6% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 0.3× | -10.0% | +8.1% |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 4.2× | 24.3% | +10.7% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | 7.7× | n/a | n/a |
Cytokinetics has 2 bonds outstanding with $891M face value.